Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of subcutaneous PF-06741086 in severe hemophilia A or B
2017-001255-31Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of marstacimab in hemophilia A and hemophilia B (HB), sponsored by Pfizer. Primary endpoint: Treatment-emergent adverse events. Started Nov 2017; status: completed.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2017-001255-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001255-31.